[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pressure-ulcer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pressure-ulcer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,43,73,97,124,150,217,239,267,298,324,346,370,391,423],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100639478","theravex-tissue-care-spray-plus-for-the-management-of-cutaneous-wounds-burns-and-chronic-ulcers-100639478",false,"NCT07617961","THERAVEX Tissue Care Spray Plus for the Management of Cutaneous Wounds, Burns, and Chronic Ulcers","Pilot Clinical Evaluation of THERAVEX Tissue Care Spray Plus for the Management of Cutaneous Wounds, Burns, and Chronic Ulcers","Inclusion Criteria\n\nAdult patients aged 18 years or older. Patients presenting with cutaneous wounds: burns, traumatic wounds, pressure ulcers, diabetic ulcers, or chronic cutaneous lesions.\n\nPatients considered clinically suitable for topical treatment with THERAVEX Tissue Care Spray Plus.\n\nExclusion Criteria Known allergy or hypersensitivity to any component of THERAVEX Tissue Care Spray Plus.\n\nPresence of severe uncontrolled systemic infection requiring immediate surgical intervention.\n\nParticipation in another interventional clinical study that could interfere with wound healing assessment.",true,"ALL","18 Years",{"count":20,"type":21},26,"ESTIMATED","OBSERVATIONAL","Pilot observational clinical evaluation assessing the safety and potential effectiveness of THERAVEX Tissue Care Spray Plus as an adjunctive topical therapy for the management of cutaneous wounds, burns, traumatic lesions, pressure ulcers, diabetic ulcers, and chronic ulcers in 26 patients. The study evaluated wound healing progression, epithelialization, tissue hydration, inflammatory response, tolerance, and overall clinical evolution in patients receiving standard wound care combined with topical application of THERAVEX Tissue Care Spray Plus. Preliminary observations demonstrated favorable tissue response, progressive epithelial regeneration, reduction of inflammatory signs, and absence of treatment-related adverse events.",[25,26,27,28,29],"Chronic Wounds","Burns","Pressure Ulcer","Traumatic Wounds","Diabetic Foot Ulcer","RECRUITING","2026-06-01",{"date":33,"type":34},"2026-06-04","ACTUAL",{"date":36,"type":34},"2025-10-02",{"date":38,"type":21},"2027-05-21",{"name":40,"class":41},"Biointelligent Technology Systems SL","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":42},"100454486","efficacy-of-hofa-versus-hydrocolloid-dressings-in-the-prevention-of-pus-in-critically-ill-prone-patients-100454486","NCT05198167","Efficacy of HOFA Versus Hydrocolloid Dressings in the Prevention of PUs in Critically Ill Prone Patients","Efficacy of Hyperoxygenated Fatty Acids Versus Hydrocolloid Dressings in the Prevention of Pressure Ulcers in Critically Ill Prone Patients","Inclusion Criteria:\n\nAll patients in prone position admitted to participating ICU who agree to be included in the study or, if they are unable to communicate, the consent is authorized by their referring family member.\n\nExclusion Criteria:\n\nPatients with previous pressure ulcers in the following prone-related locations: shoulders, thorax, genitals, iliac crest, knees, ankles, facial.",{"count":51,"type":21},262,"INTERVENTIONAL",[54],"NA","Introduction: Prone position (PP) treatment as a rescue strategy for patients with acute respiratory distress syndrome (ARDS) is a technique increasingly used in our daily practice and, as a result of the current health situation due to SARS COV-2, has become the treatment of choice for many patients. Many of the associated complications can be considerably reduced with the implementation of standardized procedures and a team trained and specialized in this technique and its subsequent care.\n\nAim: To evaluate the efficacy of the use of Hyperoxygenated Fatty Acids (HOFA) compared to the use of hydrocolloid dressings (HCD) in the prevention of Pressure ulcers (PUs) occurrence in critically ill patients in prone position.\n\nMethods: A randomized clinical trial will be conducted to compare the occurrence of PUs and other complications in patients undergoing PP in the ICU of the HUPHM. Two care groups will be formed in which HOFA and hydrocolloid dressings will be used, respectively, following a strict care protocol previously established in the unit. In addition, other variables related to medical and nursing treatment that may influence the appearance of PUs and other complications associated with PP will also be analyzed.\n\nScientific relevance: PUs have a major socioeconomic and quality of life impact on patients. Dressings and topical agents for prevention are widely used, however, it is unclear which treatment is most effective in preventing PUs in the prone patient.\n\nKeywords: Prone Position; Nursing care; Pressure ulcer; Fatty acids; Prevention; Complications.",[57,27],"Prone Position",[59,60,61,62],"Nursing Care","Fatty acids","Prevention","Complications","2026-05-12",{"date":65,"type":34},"2026-05-15",{"date":67,"type":34},"2021-06-12",{"date":69,"type":21},"2027-07",{"name":71,"class":72},"Puerta de Hierro University Hospital","OTHER",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":52,"phases":81,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":42},"100602697","phase-4-a-multicenter-prospective-clinical-trial-evaluating-a-single-layer-amniotic-membrane-and-standard-of-care-versus-matched-controls-in-the-management-of-nonhealing-pressure-ulcers-100602697","NCT07126886","A Multicenter, Prospective, Clinical Trial Evaluating a Single Layer Amniotic Membrane and Standard of Care Versus Matched Controls in the Management of Nonhealing Pressure Ulcers","Inclusion Criteria:\n\n* The potential subject must be at least 18 years of age or older.\n* The potential subject must agree to attend the weekly study visits required by the protocol.\n* The potential subject must be willing and able to participate in the informed consent process.\n* The potential subject must have a full thickness pressure ulcer NPIAP stage 3 through stage 4 without exposed bone of greater than or equal to one month in duration located on the trunk (sacral, trochanteric, or ischial).\n* At enrollment, the potential subject must have a target ulcer with a minimum surface area of 2 cm2 and a maximum surface area of 100 cm2 measured post debridement with the imaging device.\n* The potential subject has adequate off-loading of the ulcer.\n\nExclusion Criteria:\n\n* The potential subject is known to have a life expectancy of \\\u003C 3 months.\n* The potential subject's target ulcer is not a pressure ulcer.\n* The target ulcer is infected, requires systemic antibiotic therapy, or there is cellulitis in the surrounding skin.\n* The target ulcer exposes tendon or bone.\n* There is undermining at the wound edge or tunnelling.\n* There is evidence of osteomyelitis complicating the target ulcer.\n* The potential subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics).\n* The potential subject has applied topical steroids to the ulcer surface within one month of initial screening.\n* The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit(For diabetics only).\n* The surface area of the potential subject's target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit (\"historical\" run-in period). Imaging Device is not required for measurements taken during the historical run-in period (e.g., calculating surface area using length X width is acceptable).\n* The surface area measurement of the potential subject's target ulcer decreases by 25% or more during the active 2-week screening phase: the 2 weeks from the initial screening visit (S1) to the TV-1 visit during which time the potential subject received SOC.\n* The potential subject is a woman who is pregnant or considering becoming pregnant within the next 6 months.\n* The potential subject has end stage renal disease requiring dialysis.\n* The potential subject has participated in a clinical trial involving treatment with an investigational product within the previous 30 days.\n* The potential subject, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments.\n* The potential subject was treated with hyperbaric oxygen therapy (HBOT) or a Cellular, Acellular, Matrix-like Product (CAMP) in the 30 days prior to the initial screening visit.\n* The potential subject has a malnutrition indicator score \\\u003C17 as measured on the Mini Nutritional Assessment.\n* The potential subject has a known or suspected sensitivity to glutaraldehyde solutions.",{"count":80,"type":21},100,[82],"PHASE4","A multicenter, prospective, clinical trial evaluating a single-layer amniotic membrane (XPURT) and standard of care versus matched controls in the management of nonhealing pressure ulcers.",[27,85,86,87],"Ulcer, Pressure","Pressure Wound","Pressure Area","2026-02-09",{"date":90,"type":34},"2026-02-11",{"date":92,"type":34},"2025-06-11",{"date":94,"type":21},"2027-08",{"name":96,"class":41},"Applied Biologics, LLC",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":52,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":42},"100612619","pmcf-study-of-debridement-pad-100612619","NCT07255937","PMCF Study of Debridement Pad","Post Market Clinical Follow up Study to Confirm the Ongoing Safety and Performance of a Debridement Pad in Superficial, Chronic and Acute Wounds","Inclusion Criteria:\n\n* Males or females aged 18 years or above.\n* Patients who can understand and give informed consent to take part in the study.\n* Have one or more of the following wounds: Diabetic ulcers, Arterial and Venous Leg ulcers, Pressure ulcers, Postoperative wounds healing by secondary intention, traumatic and surgical wounds, and burns and scalds\n* Wounds that require debridement due to the presence of slough debris\u002Ffibrous tissue ,hyperkeratotic debris and dried exudate on the peri wound skin.\n* Wounds with both serous crusts and healthy tissue.\n* Minimum of 30% of the wound covered by debris, necrosis or slough.\n* Wound Size \\> 4cm2\n\nExclusion Criteria:\n\n* Patients who are known to be non-compliant with medical treatment\n* Patients who are known to be sensitive to any of the device components such as polyester.\n* Subject has any significant or unstable medical or psychiatric condition that, in the opinion of the Investigator, would interfere with their ability to participate in the study.\n* Subject is currently enrolled in another clinical study, or has completed a clinical study less than 30 days prior to enrolment.\n* Symptoms \\& signs of systemic and \u002F or spreading wound infection (including erythema and fever).\n* Severe pain (level 7 or higher on a 0-10 VAS or hyperaesthesia in the wound area).\n* Subjects who in the view of the investigator might not be suitable for inclusion in the study",{"count":105,"type":21},184,[54],"The design of the study is a clinical trial of Debridement Pad in subjects with superficial, chronic and acute wounds consisting of Diabetic ulcers, Arterial and Venous Leg ulcers, Pressure ulcers, Postoperative wounds healing by secondary intention, traumatic or surgical wounds and burns and scalds. The performance data from this study will support clinically meaningful rates of successful improvement in wound bed condition immediately after treatment.",[109,110,111,27,112,28,113,114],"Diabetic Ulcers","Venous Leg Ulcer","Arterial Leg Ulcer","Postoperative Wound Healing","Surgical Wounds","Burns and Scalds","2025-11-27",{"date":117,"type":34},"2025-12-01",{"date":119,"type":34},"2025-11-20",{"date":121,"type":21},"2026-07-10",{"name":123,"class":41},"Advanced Medical Solutions Ltd.",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":131,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":52,"phases":134,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":140,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":42},"100454556","phase-2-a-study-of-gm-xantho-in-pressure-ulcer-patients-100454556","NCT05199077","A Study of GM-XANTHO in Pressure Ulcer Patients","A Phase IIa Study to Investigate the Efficacy and Safety Profile of GM-XANTHO in Pressure Ulcer Patients","Inclusion Criteria:\n\n* 1\\. Female or male inpatients including in those staying in a long-term care facility, age ≥ 20 years old.\n\n  2\\. Patient who is able to understand the nature of this study and accepts to enter the study by signing written informed consent.\n\n  3\\. Patient is willing to comply with protocol-stated requirements, instructions and restrictions.\n\n  4\\. Patients who have at least 1 well diagnosed Stage 2 to 3 friction-injury associated PU (according to National Pressure Ulcer Advisory Panel \\[NPUAP\\] Staging Guidelines, 2019) as the index ulcer at Screening Visit and First Dosing Visit located in any of the following regions.\n\n  5\\. Surface dimensions of the index PU should be ≥ 5 cm2 and ≤ 50 cm2 as measured by the greatest length and width method through using an mm-scale ruler.\n\n  6\\. Patients with adequate arterial blood flow and perfusion near the site of the injury for lower extremity ulcers (e.g., the foot is warm to the touch and has palpable pulses) 7. Patients who agree discontinuation of systemic corticosteroids and systemic immune modulating agents during the study period 8. Patients who agree discontinuation of all local treatment modalities, including but not limited to topical antimicrobials, topical corticosteroid or light treatments during the study period for\u002Fon the index wound.\n\n  9\\. Patients are required to stop using treatment modalities listed in Criteria #7 and #8 at least 14 days (or longer if the treatment half-life requires so; 7 half-life should have elapsed).\n\n  10\\. Patient has adequate hematopoietic, hepatic function, nutrition condition and renal function as assessed by the following laboratory requirements to be conducted within 28 days prior to the first dosing:\n* Hemoglobin ≥ 10 g\u002FdL\n* Total WBC ≥ 3,000 cells\u002FμL\n* Platelet ≥ 55,000 counts\u002FμL without transfusion support\n* Total bilirubin ≤ 1.5× ULN and no sign of jaundice\n* ALT and AST ≤ 5× ULN and no clinical significance\n* pre-albumin ≥ 11 mg\u002FdL\n* Creatinine ≤ 1.5× ULN and no clinical significance 11. If the subject has diabetes mellitus \\[as per American Diabetes Association guidelines (ADA guideline, 2021)\\], the hemoglobin A1c (HbA1c) should be≦10 % with a stable anti-diabetes regimen (monotherapy or combination therapy including oral anti-diabetes medications) for more than 12 weeks.\n\n  12\\. All male patients and female patients with child-bearing potential (between puberty and 2 years after menopause) should use at least any one of the appropriate contraception methods shown below, for during and at least 4 weeks after GM-XANTHO treatment.\n  1. Total abstinence \\[when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception\\].\n  2. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.\n  3. Male sterilization. For female subjects on the study, the vasectomized male partner should be the sole partner for that subject.\n  4. Combination of any two of the following listed methods: (d.1+d.2 or d.1+d.3, or d.2+d.3):\n\n  d.1 Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate \\\u003C1%), for example hormone vaginal ring or transdermal hormone contraception.\n\n  d.2 Placement of an intrauterine device (IUD) or intrauterine system (IUS). d.3 Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical\u002Fvault caps) with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fvaginal suppository.\n\nExclusion Criteria:\n\n* 1\\. Surgical treatment of pressure ulcers within 30 days prior to the Screening Visit.\n\n  2\\. Patients who have any concurrent skin condition that will interfere with assessment of treatment or any condition associated with a wound healing abnormality (e.g.: connective tissue disorder or immune disorder).\n\n  3\\. Patients who have active infection on the PU site(s) at baseline 4. Patients who have known hypersensitivity to the study medication 5. Patients with chronic condition(s) which either is not stable or not well controlled.\n\n  6\\. Patients having positive results for HBV, HCV or HIV screens 7. Patients who are pregnant or breast feeding 8. Patients carry history of malignancy of any organ system (other than cervical carcinoma in situ or localized prostate cancer) within 5 years prior to study entry.\n\n  9\\. Patients had participated in investigational drug trials and took any investigational drugs within 30 days or within 5 half-life of the investigational drugs prior to the screening visit.\n\n  10\\. Patients who are not suitable to participate in the trial as judged by the Investigator(s)","20 Years",{"count":133,"type":21},58,[135],"PHASE2","This is a randomized, placebo-controlled, double-blind, 3-arm, single-center, phase IIa, parallel study to assess the efficacy, safety, and tolerability of topically applied 2.5%, 5% GM-XANTHO plus standard of care in patients with stage II or stage III pressure ulcer.",[27,138],"Diabetes Mellitus",[27],"NOT_YET_RECRUITING","2025-08-26",{"date":143,"type":34},"2025-09-03",{"date":145,"type":21},"2026-09-01",{"date":147,"type":21},"2029-04-30",{"name":149,"class":41},"Xantho Biotechnology Co., LTD",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":158,"targetDuration":160,"studyType":22,"phases":4,"briefSummary":161,"conditions":162,"keywords":181,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":42},"100230679","a-real-world-registry-of-chronic-wounds-and-ulcers-100230679","NCT02280733","A Real-World Registry of Chronic Wounds and Ulcers","A Longitudinal, Real World, Observational Registry of Chronic Wounds and Ulcers and the Patients Who Have Them","WOUNDJOURNEY","Inclusion Criteria:\n\n* Presence of one or more chronic wounds or ulcers of any etiology\n* Wound or ulcer must be treated at a participating site (which can be a hospital outpatient department, office, mobile practitioner, in the home setting, skilled nursing, etc.)\n* Care must be documented using the purpose-built, wound-specific structured electronic health record (EHR) or electronic data capture (EDC) system\n* All ages, including infants and patients aged 90 years or older (reported in aggregate in accordance with HIPAA de-identification standards)\n* All sexes and gender identities\n* All wound types and severities, including multiple wounds per patient\n\nExclusion Criteria:\n\n-None (the registry includes all eligible patients treated at participating sites without sampling or exclusion criteria)",{"count":159,"type":21},300000,"5 Years","WOUNDJOURNEY is a longitudinal, real-world, observational registry designed to capture the full clinical course and patient journey associated with chronic wounds and ulcers. Data are collected during routine care from over 1,400 clinicians across the USA and Puerto Rico using a highly structured certified electronic health record (EHR) or electronic data capture (EDC) system. Data are transmitted daily to the U.S. Wound Registry (USWR), a CMS-recognized Qualified Clinical Data Registry (QCDR). The registry captures real-time, research-ready data on patient demographics, comorbidities, wound characteristics, standard-of-care treatments, complications, and advanced therapeutics. It supports robust, fit-for-purpose real-world evidence generation by enabling risk-adjusted outcome analysis, comparative effectiveness research, and quality improvement across diverse sites of care.",[163,27,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,28,180],"Diabetic Foot","Surgical Wound Dehiscence","Vasculitis","Skin Ulcer","Leg Ulcer","Pyoderma","Peripheral Arterial Disease","Lymphedema","Surgical Complication","Venous Leg Ulcers (VLUs)","Calciphylaxis","Sickle Cell Ulcer","Pressure Ulcer (PU)","Diabetic Foot Ulcers (DFUs)","Pressure Injury","Arterial Ulcers","Soft Tissue Radionecrosis (STRN)","Chronic Ulcer",[182,183,184,185,186,187,29,110,27,177,188,189,171,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207],"Qualified Clinical Data Registry","Quality Measures","Clinical Data Research Network","Real world data","chronic wounds","chronic ulcers","Arterial Ulcer","Traumatic Wound","Pyoderma Gangrenosum","Advanced Wound Care","Skin Substitutes","CAMPs","CTPs","Negative Pressure Wound Therapy","NPWT","Collagen Dressings","Compression Therapy","Hyperbaric Oxygen Therapy","Wound Debridement","Real-World Evidence","Comparative Effectiveness","Wound Healing","Amputation","Electronic Health Record (EHR)","Debridement","Standard of Care","2025-07-10",{"date":210,"type":34},"2025-07-16",{"date":212,"type":34},"2005-01-01",{"date":214,"type":21},"2030-01",{"name":216,"class":72},"U.S. Wound Registry",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":52,"phases":226,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":42},"100592911","phase-4-evaluating-several-cellular-acellular-and-matrix-like-products-camps-and-standard-of-care-versus-matched-standard-of-care-controls-in-the-management-of-nonhealing-pressure-ulcers-100592911","NCT06999590","Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls in the Management of Nonhealing Pressure Ulcers","A Multicenter, Prospective, Randomized Controlled Modified Platform Trial Evaluating Several Cellular, Acellular, and Matrixlike Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls in the Management of Nonhealing Pressure Ulcers","Inclusion Criteria:\n\n1. The potential subject must be at least 18 years of age or older.\n2. The potential subject must agree to attend the weekly study visits required by the protocol.\n3. The potential subject must be willing and able to participate in the informed consent process.\n4. The potential subject must have a full-thickness pressure ulcer NPIAP stage 3 or stage 4 without exposed tendon or bone of greater than or equal to one month in duration located on the trunk (sacral, trochanteric, or ischial).\n5. At enrollment, the potential subject must have a target ulcer with a minimum surface area of 2 cm2 and a maximum surface area of 100 cm2 measured post-debridement with the imaging device.\n6. The potential subject has adequate off-loading of the ulcer.\n\nExclusion Criteria:\n\n1. The potential subject is known to have a life expectancy of \\\u003C 3 months.\n2. The potential subject's target ulcer is not a pressure ulcer.\n3. The target ulcer is infected, requires systemic antibiotic therapy, or there is cellulitis in the surrounding skin.\n4. The target ulcer exposes tendon or bone.\n5. The target ulcer has undermining or tunneling.\n6. There is evidence of osteomyelitis complicating the target ulcer.\n7. The potential subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics).\n8. The potential subject has applied topical steroids to the ulcer surface within one month of initial screening.\n9. The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit.\n10. The surface area of the potential subject's target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit (\"historical\" run-in period). Imaging Device is not required for measurements taken during the historical run-in period (e.g., calculating surface area using length X width is acceptable).\n11. The surface area measurement of the potential subject's target ulcer decreases by 25% or more during the active 2-week screening phase: the 2 weeks from the initial screening visit (S1) to the TV-1 visit during which time the potential subject received SOC.\n12. The potential subject is a woman who is pregnant or considering becoming pregnant within the next 6 months.\n13. The potential subject has end stage renal disease requiring dialysis.\n14. The potential subject, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments.\n15. The potential subject was treated with hyperbaric oxygen therapy (HBOT) or a Cellular, Acellular, Matrix-like Product (CAMP) in the 30 days prior to the initial screening visit.\n16. The potential subject has a malnutrition indicator score of \\\u003C17 as measured on the Mini Nutritional Assessment.",{"count":225,"type":21},500,[82],"The purpose of this study it to evaluate several cellular, acellular, and matrix-like products (CAMPs) and standard of care versus matched standard of care controls in the management of nonhealing pressure ulcers.",[27,229,85,177],"Ulcer","2025-06-03",{"date":232,"type":34},"2025-06-05",{"date":234,"type":34},"2025-05-20",{"date":236,"type":21},"2027-05",{"name":238,"class":41},"Tiger Biosciences, LLC.",{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":52,"phases":248,"briefSummary":249,"conditions":250,"keywords":254,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":42},"100462990","prosenior-prevention-of-pressure-ulcers-malnutrition-poor-oral-health-and-falls-among-older-persons-receiving-municipal-health-care-and-are-registered-in-the-quality-registry-senior-alert-100462990","NCT05308862","PROSENIOR. Prevention of Pressure Ulcers, Malnutrition, Poor Oral Health and Falls Among Older Persons Receiving Municipal Health Care and Are Registered in the Quality Registry Senior Alert","Prevention of Pressure Ulcers, Malnutrition, Poor Oral Health and Falls Among Older Persons Receiving Municipal Health Care and Are Registered in the Quality Registry Senior Alert","Inclusion Criteria:\n\n* Nursing homes registering in Senior Alert, which is a national quality registry\n\nExclusion Criteria:\n\n* not meetin inclusion criteria",{"count":247,"type":21},330,[54],"Inclusion criteria for study I and II is nurse aides, registered nurses and managers working in nursing homes who register in Senior Alert. To develop an intervention aiming to reduce the risk of pressure ulcers, malnutrition, poor oral health and falls among older persons in nursing homes, workshops will be conducted in collaboration with nurse aides, registered nurses and managers (study I). Cluster randomization is going to take place via a computerized program prior to the workshops meaning that only those nurse aides, registered nurses and managers working in nursing homes allocated to the intervention group are going to develop an intervention together with the research group and then test it (study II). The remaining nurse aides, registered nurses and managers working in nursing homes in the control group continue with regular care.",[251,27,252,253],"Fall","Malnutrition","Oral Health",[61,255,256,257],"Older people","Nursing care","Complex intervention","2025-05-07",{"date":260,"type":34},"2025-05-09",{"date":262,"type":34},"2022-01-19",{"date":264,"type":21},"2025-12-31",{"name":266,"class":72},"Malmö University",{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":52,"phases":276,"briefSummary":277,"conditions":278,"keywords":282,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":42},"100576821","polyurethane-foam-pink-pad-rct-use-in-or-100576821","NCT06790277","Polyurethane Foam-Pink Pad (RCT) Use in OR","Effectiveness of Polyurethane Foam (Pink Pad) Compared With Mepilex Dressing for Pressure Ulcer Prevention in Operating Room: A Randomized Control Clinical Trial","pink-pad","Inclusion Criteria:\n\n* Subjects ≥ 18.\n* Willing to participate.\n* Patients undergoing cardiac surgery.\n* Patient who is at risk for PU development as measured with Braden scale.\n* Patient who has skin intact and having a life expectancy greater than 72 hours as per clinical judgement.\n\nExclusion Criteria:\n\n* Subjects under 17\n* Not consenting to participate\n* Patients with suspected hypersensitivity reactions to any of the dressing formulation's ingredients.\n* Patients who are unable to continue the study because of death or change in the care setting.",{"count":80,"type":21},[54],"King Abdullah medical city has a cardiac center, and a lot of open-heart surgeries are performed there, and both polyurethane foam (pink Pad) and Mepilex dressing are applied to those patients. Therefore, the present study was designed to compare the effects of polyurethane foam (pink Pad) versus Mepilex dressing for prevention of pressure ulcer in operating room.",[279,280,281,27],"Cardiac Surgery Subjects","Pressure Ulcer Prevention","Pressure Ulcer of Skin",[283,284,285,286,287],"five layers sacral foam dressing","PINK PAD","pressure ulcers","Patients undergoing cardiac surgery","Mepilex dressing","2025-01-21",{"date":290,"type":34},"2025-01-24",{"date":292,"type":34},"2023-10-10",{"date":294,"type":21},"2025-10-10",{"name":296,"class":297},"King Abdullah Medical City","OTHER_GOV",{"id":299,"slug":300,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":52,"phases":308,"briefSummary":309,"conditions":310,"keywords":313,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":42},"100478710","the-rotational-use-of-interface-study-100478710","NCT05513508","The ROTAtional-USE of Interface STUDY","A Pragmatic Open Label, Multi-center, Spontaneous, No-profit, Randomized Controlled Clinical Trial With Non-significant Risk Medical Device on the Rotational Use of Interfaces Versus Standard of Care for Patients Treated With NPPV for AHRF.","ROTA-USE","Inclusion Criteria:\n\n* Age\\>18 years old\n* Patients with chronic obstructive pulmonary disease (COPD) exacerbation or with AHRF of a different etiology needing NPPV to avoid intubation (pH \\\u003C 7.35 with PaCO2 \\> 45 mmHg and partial pressure of oxygen (PaO2) \\\u003C 65 mmHg plus respiratory rate \\> 25 breath\u002Fmin with clinical signs of respiratory muscle distress); or as alternative to invasive ventilation with a forecast of treatment of at least 24 hours admitted to the intensive care unit, intermediate respiratory care unit, respiratory medicine service or internal medicine service according to hospital organization; or patients with chronic pulmonary disease intubated for a COPD exacerbation or for pneumonia who are early extubated and weaned in the intensive care unit with NPPV with a forecast of treatment of at least 24 hours.\n\nExclusion Criteria:\n\n* Patient with skin breakdown or non-blanchable erythema in one of the following areas i.e., nasal bridge, nasolabial fold, cheek or scalp at hospital entrance;\n* Patients who refuse to consent to the study protocol;\n* Patient known to be pregnant;\n* Patients with contraindication to NPPV (lack of spontaneous breathing; gasping; anatomical or functional airway obstruction; gastrointestinal bleeding or ileus; coma; massive agitation; massive retention of secretions despite bronchoscopy and aggressive physiotherapy; hemodynamic instability (cardiogenic shock, myocardial infarction); status post upper gastrointestinal surgery);\n* Patients entering hospital with asthma, with cardiogenic pulmonary edema;\n* Patients with tracheostomy;\n* Patients needing NPPV only for palliation of symptoms (relief of dyspnea) i.e., category 3 defined by the Task Force on the Palliative Use of NPPV of the Society of Critical Care Medicine;\n* Use of high flow nasal cannula integrated with NPPV for weaning strategy;\n* Pre-existing skin erythematosus diseases;\n* Known hypersensitivity to skin protective devices (i.e., polyurethan films, colloids, foams);\n* More than 2 hours of NPPV application before randomization;\n* Patients already included in the study protocol at an earlier stage of the hospitalization;\n* Refuse to wear NPPV interface due to comfort;",{"count":307,"type":21},478,[54],"In this trial investigators will explore if a protocolized rotational use of interfaces i.e., masks, during noninvasive positive pressure ventilation (NPPV) compared to standard care is clinically effective and cost-effective in reducing the incidence of pressure sores in patients with hypercapnic acute respiratory failure (AHRF) treated continuously i.e., for more than 24 hours, with NPPV (to avoid intubation, as alternative to invasive ventilation and after early extubation and weaning).",[27,311,312],"Noninvasive Positive Pressure Ventilation","Acute Hypercapnic Respiratory Failure",[314],"Rotational use of noninvasive interfaces","2024-11-13",{"date":317,"type":34},"2024-11-14",{"date":319,"type":34},"2022-12-08",{"date":321,"type":21},"2028-09",{"name":323,"class":72},"Azienda Ospedaliero Universitaria Maggiore della Carita",{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":331,"enrollmentInfo":332,"targetDuration":4,"studyType":52,"phases":334,"briefSummary":335,"conditions":336,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":42},"100541487","the-effect-of-pressure-ulcer-care-package-on-the-risk-of-pressure-ulcer-development-100541487","NCT06330506","The Effect of Pressure Ulcer Care Package on the Risk of Pressure Ulcer Development","The Effect of Pressure Ulcer Care Package on the Risk of Surgery-Related Pressure Ulcer Development in Patients Undergoing Orthopaedic Surgery","Inclusion Criteria:\n\n* Orthopaedics and traumatology department\n* Those who have undergone general or spinal anesthesia\n* Without any communication problems\n* Patients who volunteered to participate in the study\n\nExclusion Criteria:\n\n* Patients with pre-operative pressure ulcer\n* Those who are bedridden\n* Patients referred to the intensive care unit after surgery\n* Patients who wish to leave the study will be excluded from the study.","70 Years",{"count":333,"type":21},102,[54],"This study aimed to determine the effect of pressure ulcer care package use on the risk of pressure ulcer development due to surgery in patients undergoing orthopedic surgery. It was planned as a randomized controlled study. The population of the study will consist of patients who underwent surgery in the Orthopaedics and Traumatology Clinic of Doğubayazıt Dr.Yaşar Eryılmaz State Hospital Hospital Hospital of Ağrı Provincial Health Directorate. The sample of the study will consist of patients who volunteered to participate in the study that meets the inclusion criteria. To obtain research data, the Personal Information Form developed by the researcher in line with the literature, 3S Operating Theatre Pressure Wound Risk Assessment Scale, Pressure Wound Regions and Stages Monitoring Form prepared according to NPUAP (2016) Pressure Wound Staging System Form will be used. Statistical analysis of the data obtained from the study will be performed using the SPSS 25 (Statistical Package of Social Science) package program.",[27],"2024-08-21",{"date":339,"type":34},"2024-08-23",{"date":341,"type":34},"2024-04-10",{"date":343,"type":21},"2024-09-10",{"name":345,"class":72},"Cukurova University",{"id":347,"slug":348,"hasResults":11,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":4,"eligibilityCriteria":352,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":353,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":355,"conditions":356,"keywords":358,"overallStatus":140,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":42},"100552070","combined-molecular-and-mechanistic-methods-for-detection-of-pressure-ulcers-100552070","NCT06468306","Combined Molecular and Mechanistic Methods for Detection of Pressure Ulcers","Combined Molecular and Mechanistic Methods for Early Detection and Individual Prevention of Pressure Ulcer Formation in Vulnerable Patients","Inclusion Criteria:\n\n\\- patients that use oronasal face masks in their ordinary care during routine management regimes of non invasive ventilation.\n\nExclusion Criteria\n\n* acute respiratory failure\n* previous ICU care\n* pressure ulcer on measurement site",{"count":354,"type":21},150,"This project aims to develop a novel method for identifying early tissue damage related to pressure ulcer (PU) development in vulnerable patients by measuring biomarkers of inflammation on the skin surface. PUs are common and costly injuries that result from prolonged pressure on the skin. Current methods to assess PU risk are unreliable, and the mechanisms of PU development are not well understood. This project contributes to new knowledge of PU etiology as well as the individual variability at a molecular level combined with new knowledge about nursing actions and clinical factors linked to PU progression and outcomes of prevention. The project will use non-invasive techniques and model-based analysis to identify specific biomolecules that reflect individual susceptibility to pressure exposure in different PU risk scenarios.",[27,357],"Inflammatory Response",[27,359,360],"nursing","prevention","2024-06-20",{"date":363,"type":34},"2024-06-21",{"date":365,"type":21},"2024-08-01",{"date":367,"type":21},"2027-12-30",{"name":369,"class":297},"Linkoeping University",{"id":371,"slug":372,"hasResults":11,"nctId":373,"briefTitle":374,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":376,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":378,"conditions":379,"keywords":380,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":389,"locationsCount":42},"100549746","prevention-of-pressure-ulcers-in-patients-at-high-risk-of-developping-pressure-ulcers-using-the-low-pressure-motorized-air-support-mattress-with-xtech25-control-unit-100549746","NCT06438042","Prevention of Pressure Ulcers in Patients at High Risk of Developping Pressure Ulcers Using the Low-pressure Motorized Air Support Mattress With XTECH®25 Control Unit","Inclusion Criteria:\n\n* Patient over 18 years old\n* Patient with high risk of developing pressure ulcers (clinical judgment and a score \\\u003C= 12 on the Braden scale (6 (maximum risk) to 23 (no risk))\n* Patient without pressure injury on the day of inclusion\n* Patient up lying more than 20 hours a day on XTECH®25 mattress\n* Patient with a weight \\\u003C 200 kg\n* Patient (or a trusted third party) having been informed of the study and agreeing to participate\n\nExclusion Criteria:\n\n* Patient at end of life (estimated life expectancy less than 6 months)\n* Patient discharge from the establishment expected within two months\n* Participants will be excluded from the study if they meet the following combination of criteria indicative of malnutrition according to the 2021 Haute Autorité de la Santé guidelines (Participants must meet at least one phenotypic criterion and one etiological criterion to be considered malnourished and therefore ineligible for inclusion in the study) :\n\nA) One or more of the following phenotypic criteria:\n\n1. Significant unintentional weight loss: A weight loss of ≥ 5% within 1 month or ≥ 10% within 6 months\n2. Low Body Mass Index (BMI): BMI \\\u003C 18.5 kg\u002Fm² for individuals under 70 years old, BMI \\\u003C 21 kg\u002Fm² for individuals aged 70 years and older\n3. Reduced Muscle Mass\n4. Evident reduction in muscle mass AND\n\nB) One of the following etiological criteria:\n\n1. Inadequate nutritional intake:\n2. Nutritional intake less than 50% of the energy requirements for more than one week\n3. Reduced food intake for more than two weeks\n4. Presence of Disease or Stress Metabolism\n5. Acute or chronic illness, or any condition causing metabolic stress that increases energy requirements .",{"count":377,"type":21},80,"The aim of the study is to determine the clinical value of using a a low air pressure motorised therapeutic mattress in the prevention of pressure injury (PI) in patients at medium to high risk.\n\nThis study is noncomparative, observational study.\n\nPatients older than 18 years of age, with a high risk of PI, without PI, lying more than 20 hours a day on a XTECH®25 mattress will be included. The study will be conducted in nursing homes, and in long-stay geriatrics department.\n\nPatients are followed up for 35 days. The use of the XTECH®25 mattress is associated with the usual PI prevention measures. The primary outcome is the percentage of patients who developed between day 0 and day 35 at least one PI of at least stage 2 on the sacrum, spine, or heel. Secondary endpoints are patient assessments of comfort, caregiver satisfaction, mattress noise level, and mattress safety.",[27],[61,381,382],"Pressure ulcer","Low air pressure motorised mattress","2024-06-15",{"date":385,"type":34},"2024-06-18",{"date":387,"type":34},"2024-06-11",{"date":264,"type":21},{"name":390,"class":41},"SYSTAM",{"id":392,"slug":393,"hasResults":11,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":397,"eligibilityCriteria":398,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":399,"enrollmentInfo":400,"targetDuration":4,"studyType":52,"phases":402,"briefSummary":403,"conditions":404,"keywords":409,"overallStatus":140,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":4},"100544500","ideal-skiin-cares-bundle-to-prevent-pressure-injury-100544500","NCT06369688","IDEAL SKIIN CARES Bundle to Prevent Pressure Injury","Effect of IDEAL SKIIN CARES Bundle to Prevent Hospital-acquired Pressure Injury: A Cluster Randomized Clinical Trial","IdealSkinCares","Inclusion Criteria:\n\n* be adults aged 18 years or older;\n* have been hospitalized for a minimum of 48 hours;\n* be willing to participate.\n\nExclusion Criteria:\n\n* patients with significant pre-existing skin conditions or injuries that make it difficult to observe skin integrity;\n* have existing PIs or vascular ulcers upon admission to the hospital (pressure injuries defined by the National Pressure Ulcer Advisory Panel);\n* be at risk of PIs due to limited mobility (requiring physical or mechanical assistance to reposition or move);\n* individuals with urinary or fecal incontinence, mental illness, or severe cognitive impairment upon hospital admission;\n* patients who are hospitalized in day-surgery, critical care, emergency, maternity, pediatrics, mental health and dialysis units;\n* admitted to the hospital for \\>28 days;\n* those with prior experience of PIs or training in PIs care and prevention.","90 Years",{"count":401,"type":21},1620,[54],"The study will be a multi-center, triple-blinded, cluster randomized controlled trial (c-RCT) conducted with a three-arm parallel design and a 1:1:1 allocation ratio. The experimental groups will consist of two arms: the intervention group, where patients will receive training in relevant pressure injury care bundles, and the placebo group, where patients will receive training in an irrelevant topic like respiratory care. Both intervention and placebo groups will receive specialized pressure injury prevention (PIP) care bundle from trained wound specialist nurses (WSNs). The third arm will be the control group comprising patients who do not undergo any training course and will receive only routine standard care for PIP care bundle. The aim of c-RCT will be to compare the incidence of hospital-acquired pressure injury (HAPI) in the three study groups and to provide detailed evidence on the effect of the developed pressure injury care bundle, administered by WSNs on the development of HAPI in trained hospitalized patients, as opposed to those receiving routine standard care for PIP care bundle without training.",[27,177,405,406,407,408,166],"Bed Sore","Pressure Sore","Decubitus Sore","Decubitus Ulcer",[177,410,411,412,413],"Care Bundle","Hospital-acquired pressure injury","Randomized Clinical Trial","IDEAL SKIIN CARES","2024-04-15",{"date":416,"type":34},"2024-04-17",{"date":418,"type":21},"2025-10-01",{"date":420,"type":21},"2027-10-01",{"name":422,"class":72},"Baqiyatallah Medical Sciences University",{"id":424,"slug":425,"hasResults":11,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":430,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":432,"conditions":433,"keywords":436,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":42},"100494051","treatment-of-osteomyelitis-associated-pressure-ulcers-by-surgical-flaps-and-anti-bacterial-agents-100494051","NCT05713149","Treatment of Osteomyelitis-associated Pressure Ulcers by Surgical Flaps and Anti-bacterial Agents","Treatment of Osteomyelitis-associated Pressure Ulcers by Surgical Flaps and Anti-bacterial Agents in Patients Patients With Neuromotor Disability : a Prospective Cohort Study","Inclusion Criteria:\n\n* Patients \\>= 18 years old ;\n* Treated in the Perioperative Disability Unit (UPOH) of the Physical Medicine and Rehabilitation Department of our university hospital;\n* Admitted for the treatment of an osteomyelitis-associated pressure ulcer by surgical flap;\n* Having a neuromotor disability;\n* No opposition to be enrolled in the study from the patient, or from a legally authorized close relative if the patient's state of health does not allow it;\n* Affiliation to a social security scheme.\n\nExclusion Criteria:\n\n* Under court protection.",{"count":431,"type":21},400,"People with neuromotor disability (i.e. following an inborn or acquired spinal cord, cerebral or peripheral neurological lesion) are at high risk of osteomyelitis-associated pressure ulcers.\n\nThe management of osteomyelitis-associated pressure ulcers is controversial. In our center, patients benefit from a one stage surgical management with bone shaving and flap covering osteitis of pressure ulcer to perform wound closing. Surgery is followed by an antibiotic treatment, secondarily adapted to intraoperative samples.\n\nThe aim of this study is to describe the cohort and to identify factors associated with failure (or success) in this frail population.",[434,27,435],"Disability or Chronic Disease Leading to Disablement","Osteomyelitis",[437],"Disability, Pressure Ulcer, Osteomyelitis, Surgical Flaps, Anti-bacterial agents, Posture","2023-02-18",{"date":440,"type":34},"2023-02-21",{"date":442,"type":34},"2023-02-19",{"date":444,"type":21},"2027-02-01",{"name":446,"class":72},"Institut de Sante Parasport Connecte Synergies"]